

Index

- abuse. *See* emotional abuse; physical abuse; psychological abuse; sexual abuse
- acupuncture, 113
- acute stress disorder, 105–106
- AD. *See* Alzheimer's disease
- adaptive personality traits, 249
- addiction. *See also* pregnancy, addiction and; treatment strategies, for addiction
- abuse history as factor in, 186
- in adolescence, 177–179
- age of onset for, 177–179
- assortive mating and, 188
- through AUDIT, 176
- biological risk factors for, 183–185
- CDT levels and, by gender, 176
- to club drugs, 175
- consequences of, 177–181
- defined, 174–176
- depression and, 185
- development course of, 177–181
- diagnosis of, 176
- DSM-V classification in, 174–175
- in elderly populations, 182–183
- to electronic cigarettes, 175–176
- epidemiology of, 176–177
- estrogen and, 184
- as excessive appetite, 181
- GAD and, 186
- to gambling, 175
- genetic factors for, 185
- among girls, 177–179
- history of, 174
- ICD-10 classifications, 174–175
- identification of, 176
- among lesbian women, 185
- lifespan consequences of, 183–184
- metabolic factors for, 183–184
- in middle age, 182
- national consumption patterns and, 176–178
- neurobiological factors for, 184–185
- from online access to drugs, 175
- opponent process theory of, 181
- personality disorders and, 186
- physical harms of, 184
- psychological comorbidity for, 185–186
- PTSD and, 186
- relapsing nature of, 183–184
- risk factors for, 183–185
- sex hormones and, 184
- for sex workers, 186
- social factors for, 186–187
- substance misuse compared to, 175
- suicide and, 185–186
- telescoping effect of, 183
- theories of, 180–181
- transition to problematic use, 179–180
- transtheoretical model of behavior change theory for, 181
- during young adulthood, 177–179
- addiction disorders, 177
- GAD and, 222
- prevalence of, 177–179
- ADHD. *See* attention deficit hyperactivity disorder
- adjustment disorder, 105
- adolescence. *See also* pubertal development
- AN during, 201
- addiction development in, 177–179
- affective disorders during, gender differences in, 65–66
- anxiety disorders during, 65
- BDD during, 199
- BED during, 202
- BN during, 202
- BPD during, 141
- brain development during, 71–72
- depression during, 65
- gender gap theories and, 66–73
- gender intensification hypothesis and, 66–69
- PTSD during, 209–210
- adoptive parents, mental illness and, 114
- affective disorders. *See also specific disorders*
- emotional expression and, 69–70
- evolutionary synthesis of, 73–75
- gender differences in, during adolescence, 65–66
- personality differences and, 69–70
- pubertal development and, 70–71
- pubertal influences on, 73–75
- unplanned pregnancies and, 90
- affective suffering, 250
- African-Americans. *See also* Black and ethnic minority women
- depression for, 253
- PTSD in, 209
- aging. *See also* elderly women; late-life depression
- adaptive personality traits as part of, 249
- anxiety disorders and, 249
- cultural perceptions of, 247
- Geriatric Anxiety Inventory, 258
- psychiatric assessment of, 247–248
- psychological development and, 248–249
- suicide and, 250
- agomelatine, 255–256
- agoraphobia, 223–224
- comorbidity for, 224
- diagnostic criteria for, 223–224
- PTSD and, 224
- alcohol abuse. *See also* addiction
- mortality rates with, 183
- in pregnant women, 180
- Alcohol Use Disorders Identification Test (AUDIT), 176
- Alcoholics Anonymous, 189
- Allan, Claire, 5–6
- alprazolam, 258–259
- Alzheimer's disease (AD)
- depression and, 250
- epidemiology of, 337
- ERT for, 84–85
- female hormonal development, 84–85
- sex hormones and, 84–85
- VLOS and, 324–327
- amenorrhoea, 300
- hyperprolactinaemia and, 311
- valproate and, 311
- amitriptyline, 255–256
- AN. *See* anorexia nervosa
- animals, maternal behavior in, 32–33
- cross-generational transmission of, 33
- LG-ABN and, 33
- anorexia nervosa (AN), 200
- during adolescence, 201

- clinical course for, 201
- clinical features of, 200
- epidemiology of, 200–201
- prevalence rates of, 200–201
- subtypes of, 200
- anticonvulsant face, 277–291
- antidepressants. *See also specific drugs*
 - breastfeeding and, 125
 - in late pregnancy, 124–125
 - neurodevelopment in children after, 125
 - pharmacokinetics of, 124
 - during pregnancy, 123–125
 - reproductive safety of, 124
 - for schizophrenia, 308, 312
 - SNRIs, 214
 - SSRIs, 124–125, 214
 - TCA, 124
- anti-epileptic mood stabilisers
 - for BD, 128–130
 - breastfeeding and, 129–130
 - carbamazepine, 93, 95–96, 128–130
 - congenital anomalies as result of, 128–129
 - lamotrigine, 128–130
 - neurodevelopmental effects of, 129
 - pharmacokinetics of, 128
 - during pregnancy, 128–130
 - spontaneous abortions as result of, 129
 - valproate, 93, 95–96, 128–130
- antihistamines, 312
- antipsychotic drugs
 - for BD, 282–291
 - breastfeeding and, 128, 282
 - congenital anomalies as result of, 126
 - diabetes and, 126–127
 - first generation, 282
 - hyperprolactinaemia and, 311
 - infant birth weight and, 126–127
 - neonatal effects of, 127
 - neurodevelopmental effects of, 127–128
 - pharmacokinetics of, 125–128
 - phenothiazines, 126
 - during pregnancy, 125–128
 - for schizophrenia, 308–311
 - second generation, 282–291
- antisocial personality disorder (ASPD), sex differences in, 138
- anxiety disorders. *See also specific disorders*
 - during adolescence, 65
 - aging and, 249
 - barriers to care for, 259–260
 - BD and, 271–272
 - depression and, 220
 - differential diagnosis of, 106
 - disability as result of, 220
 - in elderly women, 228, 258–259
 - fetal development and, 108–109
 - maternal caregiving and, 36–37
 - menstrual cycle as influence on, 226–227
 - non-pharmacological interventions, 258–259
 - perinatal, 227–228
 - pharmacological treatments for, 258–259
 - PMDD and, 226
 - during pregnancy, 104–105, 108–109
 - prevalence of, 220
 - prevention strategies, 110–111
 - primary prevention approaches to, 260–261
 - prognosis projections for, 259–260
 - risk factors for, 253
 - secondary prevention approaches to, 260–261
- anxiolytic and hypnotic drugs. *See also specific drugs*
 - breastfeeding and, 131
 - for elderly populations, 258–259
 - floppy baby syndrome, 131
 - during pregnancy, 130–131
- ASD. *See* autism spectrum disorders
- Asperger, Hans, 56–62
- assortive mating, 188
- atenolol, 258–259
- attention deficit hyperactivity disorder (ADHD), prenatal stress and, 82
- AUDIT. *See* Alcohol Use Disorders Identification Test
- Australia
 - cultural assimilation in, 16
 - domestic violence in, 163
- autism spectrum disorders (ASD), 55–61
 - ascertainment bias against females, 58, 60–61
 - biological mechanisms, 58–61
 - camouflage and, 57–58
 - defined, 55
 - extreme male brain theory, 57
 - features presentation for, in males, 55–56
 - gender bias in clinical studies, 55
 - genetic influences on, 58–59
 - hormonal effects, 59–60
 - misdiagnosis of, for females, 60–61
 - neurobiological differences for, by gender, 60
 - OT and, 60
 - prenatal stress and, 82
 - restricted patterns of interests in, 57–58
 - social mimicry and, 57–58
 - stereotyped patterns of interests in, 57–58
 - testosterone and, 59–60
 - vasopressin and, 60
 - X-chromosomes and, 58
- BD. *See* bipolar disorder
- BD I. *See* bipolar disorder I
- BD II. *See* bipolar disorder II
- BDD. *See* body dysmorphic disorder
- BDPs. *See* benzodiazepines
- BED. *See* binge eating disorder
- benzodiazepines (BDPs), 130–131, 258
 - for BD, 280–282
 - breastfeeding and, 282–283
 - floppy baby syndrome and, 131
 - for schizophrenia treatment, 312
 - for VLOS, 329
- binge eating disorder (BED), 202
 - during adolescence, 202
 - clinical course of, 202
 - clinical features of, 202
 - epidemiology of, 202
- bipolar disorder (BD)
 - age of onset for, 269
 - anti-epileptic mood stabilisers for, 128–130
 - anxiety disorders and, 271–272
 - BDPs for, 280–283
 - BPD and, 272
 - breastfeeding and, 281–283
 - carbamazepine for, 282
 - CBT for, 274–275
 - comorbidity with, 271–272
 - eating disorders and, 272
 - ECT for, 280
 - estrogen and, 84
 - female reproduction and, 84–86
 - first generation antipsychotics for, 282
 - gender differences in, 269
 - IPSRT for, 274–275
 - IPT for, 274–275
 - lamotrigine for, 278–282
 - lithium for, 276–277, 281
 - management strategies for, during pregnancy, 274–280
 - medical conditions and, 272
 - panic disorder and, 272
 - paternal psychopathology and, 274
 - pharmacotherapy principles for, 275–276
 - PMS and, 272–273
 - preconception counseling with, 273
 - during pregnancy, 95, 101–104, 274
 - prevalence rates for, 269–291
 - psychotropic medications for, 276
 - rapid cycling with, 269
 - reproductive health and, 272–273

Index

- bipolar disorder (BD) (cont.)
 screening for, 271
 second generation antipsychotic drugs for, 282–291
 social support and, 275
 substance abuse and, 272–291
 topiramate for, 282
 untreated maternal, 273–274
 valproate for, 278–281
 yoga therapy for, 113, 275
- bipolar disorder I (BD I)
 BD II compared to, 271
 depressive episodes in, 270
 manic episodes in, 270
 postpartum psychosis and, 270
 relapse risks with, 270
 symptoms of, 270–271
- bipolar disorder II (BD II)
 BD I compared to, 271
 hypomania with, 271
 MDD and, 271
 symptoms of, 271
- black and ethnic minority (BME)
 women, mental health for, 14.
See also South Asians
- CSA and, 19
 cultural bereavement, 21, 23
 depression among, 18–22
 FGM and, 20
 gender-based violence and, 19–20
 intersectional approach to, 21–22
 migration and, 21
 perinatal depression, 18
 policy and practices influenced by, 23–24
 PTSD, 19
 research parameters for, 16–18
 sex trafficking and, 20
 social status of, 22
- Bleuler, Manfred, 320
- blood-injection injury phobia, 105
- BME women. *See* Black and ethnic minority women
- BN. *See* bulimia nervosa
- body dysmorphic disorder (BDD), 198–200
 during adolescence, 199
 age of onset for, 199
 chronicity of, 203
 clinical course of, 199
 clinical features of, 198
 comorbidity for, 202–203
 compulsive behaviors with, 198
 diagnostic criteria, 198
 epidemiology of, 198–199
 in females, 200
 prevalence rates for, 198–199, 203
 under-diagnosis of, 199
- body image
 evaluation of, 197
 investment in, 197
 as multidimensional construct, 197
 sociocultural models of, 197–198
 in Western cultures, 197
- body image disorders. *See* eating disorders; *specific disorders*
- borderline personality disorder (BPD), in females
 during adolescence, 141
 BD and, 272
 clinical presentation of, 140–142
 co-occurring disorders for, 141–142
 criteria for, 137
 diagnostic bias for, 139
 functioning with, 142–143
 heritability of, 143
 longitudinal course and, 142–143
 neurobiology of, 143–144
 overview of, 137–138
 prevalence in population samples, 138–139
 risk factors for, 143
 sampling bias for, 139
 sex differences in, 138, 140–142
 social constructivism and, 139–140
 symptom criteria for, 140
 temporal stability and, 142–143
 underlying behaviours and traits for, 140–141
- brain development. *See also* sex differences, in brain development
 empathizing brain, 56
 for females, hormone-induced, 48–49
 for males, hormone-induced, 48
 pubertal development and, 71–72
 schizophrenia and, 297–300
 SDN-POA in, 45–46
 sexual differentiation in, genetic contributions to, 46–47
 steroid hormone regulation, 47–48
 systemizing, 56
 white matter in, 72
- breastfeeding
 antidepressant drugs and, 125
 anti-epileptic mood stabilisers and, 129–130
 antipsychotic drugs and, 128, 282
 anxiolytic and hypnotic drugs and, 131
 BD and, 281–283
 BDPs and, 282–283
 carbamazepine and, 129–130, 282
 lamotrigine and, 129–130, 282
 lithium and, 130, 281
 as OT proxy, 35–36
 psychotropic medications and, 123
- topiramate and, 282
 valproate and, 129–130, 281–282
- bright light therapy, 113
- British Crime Survey, 161–162
- bromocriptine, 94
- bulimia nervosa (BN), 201–202
 during adolescence, 202
 age of onset for, 202
 clinical features of, 201
 AN compared to, 202
 epidemiology of, 201–202
 prevalence rate for, 201–202
- bupropion, 255–256
- buspirone, 258–259
- cabergoline, 94
- Canada, cultural assimilation in, 16
- Canadian Network for Mood and Anxiety Treatments (CANMAT), 274
- carbamazepine, 93, 95–96, 128–130
 anticonvulsant face, 278–282
 for BD, during pregnancy, 278–282
 breastfeeding and, 129–130, 282
 carbohydrate deficient transferrin (CDT) levels, 176
- Cardiac Randomized Evaluation of Antidepressant Psychotherapy (CREATE), 239–240
- cardiovascular disease (CVD), 239
- caregivers, women as, 4
 challenges of, 28–29
 for dementia, 342–343
 emotional distress for, 28–29
 intervention strategies for, 29
 longevity for, 29
 positive outcomes for, 29–30
 prevalence patterns, 28
 range of activities for, 28
 in schizophrenia treatments, 314–315
- CBSST. *See* Cognitive Behavioural Social Skills Training
- CBT. *See* cognitive behavior therapy
- CDT levels. *See* carbohydrate deficient transferrin levels
- Charles Bonnet syndrome, 328
- child sexual abuse (CSA), among BME women, 19
- childbirth
 depression influenced by, 93
 schizophrenia influenced by, 93
- child-centered interventions, 39–40
- childhood
 hormonal development during, 83
 maternal depression during, exposure risks, 109
 trauma during, 83

- childhood-onset schizophrenia, 298–299
- Children’s Act, 98
- chronic obstructive pulmonary disease, 253
- citalopram, 124, 239–240, 255–256
- clozapine, 282, 308
- club drugs, 175
- cocaine use. *See also* addiction
- during pregnancy, 181–182
- coercive behavior, domestic violence and, 162
- cognitive behavior therapy (CBT), 7
- for BD, 274–275
- after domestic violence, 170
- for late-life depression, 254
- during pregnancy, mental illness and, 111–112
- for PTSD, 214
- for schizophrenia, 313–314
- Cognitive Behavioral Social Skills Training (CBSST), 329
- cognitive bias, by gender, 56
- cognitive remediation therapy, 313–314
- Cognitive Trauma Therapy, 170
- compensatory model, for addiction treatment, 187
- congenital malformations, 37–38
- continuation therapy, 261
- controlling behaviors, 162–163
- domestic violence and, 162
- coping styles, 252
- cortisol, 82–83
- counseling and care, for preconception, 92–94, 273
- CREATE. *See* Cardiac Randomized Evaluation of Antidepressant Psychotherapy
- criminal offenses, by women. *See also* prisoners, women
- characteristics of victims, 151
- demographics for, 148–155
- filicide, 151
- homicide, 151–152
- male offenders compared to, 148–150
- offense rates, 148
- for violent acts, 150–151
- CSA. *See* child sexual abuse
- cultural bereavement, 21, 23
- culturally-capable care, 24
- culturally-competent care, 24
- culture. *See also* Black and ethnic minority women; ethnicity
- assimilation and, 16
- body image influenced by, 197
- doctor and patient relationships
- influenced by, 15
- egocentric, 16
- 5 dimensions of, 22–23
- fluidity of, 15–16
- gender-based stereotypes and, 17
- intersectional approach to, 21–22
- masculine, 22–23
- mental health policy influenced by, 23–24
- multiple identities and, 15
- PTSD and, 209
- social construction of, 15–16
- CVD. *See* cardiovascular disease
- cytokines, 238
- DBT. *See* dialectic behavioral therapy
- dementia. *See also* Alzheimer’s disease
- clinical presentation of, 338–339
- defined, 337
- diet as factor for, 340
- education level as factor for, 340
- epidemiology of, 337–338
- FTD, 327, 338
- hormone replacement therapy and, 340–341
- hysterectomies as factor for, 340
- late-life depression and, 342
- Lewy body, 337–338
- MCI and, 341
- neuroticism and, 341
- parenting and, 340
- PD, 327, 338
- risk factors for, 339–342
- sex hormones and, 340
- stress and, 341
- treatment approaches to, 342
- vascular, 337
- depression. *See also* late-life depression;
- postpartum depression
- addiction and, 185
- during adolescence, 65
- aetiology of, 106–107, 233
- for African Americans, 253
- anxiety disorders and, 220
- among BME women, 18–22
- case identification, 109–110
- childbirth as influence on, 93
- classification of, 249–250
- CVD and, 239
- differential diagnosis for, 106
- domestic violence and, 163–164
- estrogen and, 70–71, 111, 252
- female hormonal development and, 83–84
- female reproduction and, 83–84
- fetal development and, 108–109
- GAD and, 222
- gender gap in, 65–75
- gender intensification hypothesis and, 68
- gender roles and, 69
- in girls, 65–75
- in Hispanics, 253
- HPA axis and, 233
- maternal caregiving and, 36–37
- medications as cause of, 251
- menstrual cycle influences on, 237–238
- minor, 249–250
- OCD and, 226
- during perimenopause, 85, 238–239
- perinatal, 18, 101–104, 108–109, 238
- PMDD, 83–84, 237
- PMS and, 237–238
- during pregnancy, 18, 101–104, 108–109
- pubertal development and, 237
- quality of life issues with, 239–240
- reproductive, 83–84, 233–239
- resistant, 257–258
- risk factors for, 106–107
- sex hormones and, 83–84
- sexual selection and, 74–75
- social risk hypothesis of, 73–75
- among South Asian women, 18
- SSRIs for, 124–125, 239–240
- STAR-D, 109
- stress and, 73
- subsyndromal, 249–250
- sub-threshold, 250
- testosterone and, 70–71
- WHO predictions for, 233
- diabetes, antipsychotic drugs and, 126–127
- Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition) (DSM-5), 140–141
- addiction classification in, 174–175
- Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) (DSM-IV), 139
- dialectic behavioral therapy (DBT), 154
- diazepam, 258–259
- diet, dementia and, 340
- disease, illness compared to, 17
- disease model, for addiction treatment, 187
- distress. *See also* embodied distress
- for female caregivers, 28–29
- DNA methyltransferase (DNMT), 49
- domestic violence
- advocacy strategies for, 168–170
- in Australia, 163
- causes of, 164
- CBT after, 170

Index

- domestic violence (cont.)
 coercive behavior and, 162
 Cognitive Trauma Therapy after, 170
 controlling behaviors and, 162
 criteria for, 162–163
 depression and, 163–164
 escape strategies for victims, 164–165
 health care responses to, 165–167
 health impacts of, 163–164
 ICD-10 classification for, 174–175
 IPV as, 97, 162–163
 mental disorders and, 163–164
 mental health professionals' role in, 165–166
 multi-level interventions for, 164, 168–170
 nature of, 162–163
 PAFs and, 170
 Power and Control Wheel for, 167
 prevalence of, 161–162
 PTSD and, 162–164
 as public health issue, 161–162
 recognition of, 166–167
 risk assessment of, 167
 selective inquiries about, 166–167
 specialist referrals, 167–168
 support strategies for, 168
 in UK, 163
 WHO action guidelines, 165–166
- dothiepin, 255–256
- double jeopardy, 14
- drugs. *See also* addiction
 club, 175
 cocaine, 181–182
 online access to, 175
- DSM-IV. *See* *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition)
- DSM-5. *See* *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition)
- duloxetine, 255–256
- dysthymia. *See* persistent depressive disorder
- early-onset schizophrenia, 298–299
- eating disorder not otherwise specified (EDNOS), 203
- eating disorders, 200–203. *See also*
 anorexia nervosa; binge eating disorder; bulimia nervosa
 BD and, 272
 comorbidity for, 202–203
 historical documentation of, 200
 OCD and, 226
- Ebstein's anomaly, 276
- ECT. *See* Electroconvulsive Therapy
- Edinburgh Postnatal Depression Scale (EPDS), 110
- EDNOS. *See* eating disorder not otherwise specified
- ego integrity, 253, 327
- egocentric culture, 16
- elderly women. *See also* late onset schizophrenia; late-life depression; very-late-onset-schizophrenia-like-psychosis
 addiction among, 182–183
 anxiety disorders in, 228, 258–259
 in classical mythology, 247
 coping styles in, 252
 personality in, 252
 sexual interest for, 248–249
- Electroconvulsive Therapy (ECT), 112–113
 for BD, 280
 for late-life depression, 257–258
- electronic cigarettes, 175–176
- embodied distress, 4
- female identification of, 23
- emotional abuse, 162–163
 addiction and, 186
- emotional processing theory, 213
- Emotionally Unstable Personality Disorder, 153
- emotions
 affective disorders and, 69–70
 gender differences and, 70
 gender roles and, 69–70
 negative, 69
 pubertal development and, 71–72
 public expressions of, for women, 5–6
- empathizing brain, 56
- employment. *See* paid work
- Enhancing Recovery in Coronary Heart Disease (ENRICH), 239–240
- environmental influences
 epigenetics and, 52
 genetics and, 52
 on mental health, 51
 neuroepigenetics and, 52
- EPDS. *See* Edinburgh Postnatal Depression Scale
- epigenetics
 DNMT and, 49
 environmental influences and, 52
 mental health influenced by, 51
 origins of, 49
 for resilience, 50–51
 risk for disorders, 49–50
 in sexual differentiation of brain, 49
- ERT. *See* estrogen replacement therapy
- escitalopram, 255–256
- estrogen, 70–71, 84, 234–241
 addiction and, 184
 depression and, 70–71, 252
 for postpartum depression, 111
 for postpartum psychosis, 111
 for schizophrenia, 300, 313
 VLOS and, 324
- estrogen replacement therapy (ERT), 84–85
- ethnicity. *See also* black and ethnic minority women; race
 defined, 14
 intersectional approach to, 21–22
 as self-ascribed, 14
 in UK, stereotypes in, 22
- European Medicines Agency, 129
- extreme male brain theory, 57
- family planning, for women with mental illness, 94
- Family SMILES, 39–40
- family therapy, 313–314
- FASD. *See* Fetal Alcohol Spectrum Disorder
- fathers
 BD in, 274
 during pregnancy, 114
- female genital mutilation (FGM), 20
- female reproduction. *See also*
 childbirth; preconception; pregnancy
 BD and, 84–86
 bipolar disorder and, 272–273
 depression and, 83–84
 estrogen and, 84
 hormonal development and, 83–84
 menstrual cycle and, 226–227
 OCD and, 226
 PMDD and, 83–84
 psychotropic medication and, 93
 reproductive depression, 83–84
 schizophrenia and, 84–86
 service care implications for, 91–92
 in women with mental illness, 91–92, 94–98
- fertility, for women with mental illness, 93–94
- Fetal Alcohol Spectrum Disorder (FASD), 181
- fetal development. *See also* in utero, hormonal development
 anxiety disorders and, 108–109
 depression and, 108–109
 testosterone levels during, 81–82
- fetal valproate syndrome, 277–291
- FGM. *See* female genital mutilation
- filicide, 151
- first generation antipsychotic drugs, 282
- floppy baby syndrome, 131
- fluoxetine, 124, 255–256

- fluvoxamine, 255–256
 frontotemporal dementia (FTD), 327, 338
- GAD. *See* Generalized Anxiety Disorder
- Gamblers Anonymous, 189
- gambling addiction, 175
- gamma butyrolactone (GBL), 175
- gamma hydroxybutyrate (GHB), 175
- gastric emptying, 307
- GBL. *See* gamma butyrolactone
- GDS. *See* Geriatric Depression Scale
- gender. *See also* girls; males; sex differences, in brain development; socialization, gender and; women affective disorders and, during adolescence, 65–66 anxiety disorders and, 65 ASD and, neurobiological differences by, 60 ASPD and, 138 BD and, 269 BPD and, 138, 140–142 CDT levels by, 176 cognitive bias and, 56 cultural stereotypes, 17 emotionality and, 70 HPA axis expression, 234–236 infanticide and, 2 mental health policy influenced by, 23–24 mental health provisions and practices and, 7–8 neuroendocrine system and, 234–236 neuroimaging and, 236–237 panic disorder and, 222–223 personality disorders and, 138 poverty and, 3 power relations and, 1–2 PTSD and, 209–214 SAD and, 225 schizophrenia and, 295, 307 serotonergic neurotransmitters and, 233–234 survival strategies and, 6–7 unpaid work and, 4 VLOS and, 323–325
- gender bias
 in ASD studies, 55
 in DSM-IV criteria, 139
- gender gap
 gender intensification hypothesis for, 66–69
 recall artefact, 65–75
 theories for, emergence during adolescence, 66–73
- gender inequality, 1
 embodied distress and, 4
 ideology and, 6
 through interpersonal violence and abuse, 1–3
 resource access and, 4–5
- gender intensification hypothesis
 during adolescence, 66–69
 depression and, 68
 limitations of, 68–69
 socialization and, 66
 timing in, 68
- gender roles
 depression and, 69
 emotional expression and, 69–70
 evolutionary development of, 56
 gender intensification hypothesis and, 66–69
 individual differences in personality and, 69–70
 masculinity, 5–6, 69
 neuroticism and, 69
 socialization of, through parenting, 66–72
- gender-based violence. *See* violence, gender-based
- gender-responsive treatment (GRT), 155
- Generalized Anxiety Disorder (GAD), 104, 186, 221–222
 addiction disorders and, 222
 age of onset for, 221–224
 clinical course of, 221
 comorbidity for, 221–222
 depression and, 222
 epidemiology of, 221
 risk factors for, 221
 symptoms of, 221
- genetics
 addiction and, 185
 ASD and, 58–59
 BPD and, 143
 environmental influences and, 52
 mental health risks and, 51
 mental illness and, during pregnancy, 107
 OCD and, 226
 preconception counseling and, 273
 sexual differentiation of brain influenced by, 46–47
- Geriatric Anxiety Inventory, 258
- Geriatric Depression Scale (GDS), 253–254, 254
- GHB. *See* gamma hydroxybutyrate
- girls. *See also* hormonal development, in females
 abuse of, 1–2
 addiction among, 177–179
 depression in, 65–75
- estrogen and, 70–71
 gender-based violence against, 1–3
 gendered power relations for, 1–2
- GRT. *See* gender-responsive treatment
- HCP. *See* Human Connectome Project
- HD. *See* Huntington's Disease
- Health and Social Care Act, 152
- Herman, Judith, 164
- hidden minorities, 23
- Hispanics, depression in, 253
- homicide, 151
 mental illness and, 151–152
- honor killings, 2
- hormonal development, in females
 brain development and, 48–49
 during childhood, 83
 depression and, 83–84
 ERT, 84–85
 estrogen, 70–71
 memory impairment and, 84–85
 mood influenced by, 85
 perimenopause and, 85
 physical abuse and, 83
 PMDD and, 83–84
 during postreproductive years, 84–85
 during reproductive years, 83–84
 schizophrenia and, 300
 in utero, 81–83
- hormone replacement therapy, 258
- dementia and, 340–341
- hormones. *See also* sex hormones; specific hormones
 ASD and, 59–60
 brain development and, in males, 48
 during pregnancy, mental illness and, 107–108
 PTSD and, 213
 steroid regulation, 47–48
 as treatment strategy, during pregnancy, 112
- HPA axis. *See* hypothalamic pituitary adrenal axis
- Human Connectome Project (HCP), 236
- Huntington's Disease (HD), 327
- hyperprolactinaemia, 311
- hypnotics, 312
- hypochondriasis, 253
- hypoglycaemia, 253
- hypomania, 271
- hypo-estrogenemia, 300
- hypothalamic pituitary adrenal (HPA) axis, 83
 depression and, 233
 sex differences, 234–236
 sexual abuse and, 235
- hysterectomies, 340

Index

- IBS. *See* irritable bowel syndrome
 ICD-10. *See International Classification of Diseases 10th Edition*
 identity
 culture and, 15
 socialization and, 1–6
 ideology, gender inequality and, 6
 illness, disease compared to, 17
 imipramine, 255–256
 Incredible Years/Dinosaurs Schools, 39
 inequality. *See* gender inequality
 infant attachment, 32, 38–39
 infant birth weight, 126–127
 infanticide, 151
 gender and, 2
 postpartum psychosis and, 274
 infants, with congenital malformations, 37–38
International Classification of Diseases 10th Edition (ICD-10), 174–175
 interpartner violence (IPV), 97, 162
 psychological abuse and, 163
 interpersonal and social rhythm therapy (IPSRT), 274–275
 interpersonal psychotherapy (IPT), 111–112
 for BD, 274–275
 for late-life depression, 254
 intersectional approach, for BME women's mental health, 21–22
 intervention strategies
 for anxiety disorders, 258–259
 for BD, during pregnancy, 274–275
 child-centered, 39–40
 for domestic violence, 164, 168–170
 for female caregivers, 29
 for female prisoners, 153–155
 for late-life depression, 255–257
 parent-centered, 38–39
 for parenting experiences, 38–40
 for PTSD, 214
 intimidation, 162–163
 IPSRT. *See* interpersonal and social rhythm therapy
 IPT. *See* interpersonal psychotherapy
 IPV. *See* interpartner violence
 irritable bowel syndrome (IBS), 236
 Itzin, Cathy, 91
 ketamine, 175
 lamotrigine, 128–130
 for BD, during pregnancy, 278–282
 breastfeeding and, 129–130, 282
 late onset schizophrenia
 history of, 320–321
 neuroimaging of, 326–327
 nosology for, 320–321
 late-life depression
 AD and, 250
 affective suffering and, 250
 antidepressants for, 254–256
 assessment of, 253–254
 barriers to care for, 259–260
 CBT for, 254
 comorbidity for, 251–252
 continuation therapy after, 261
 dementia and, 342
 diagnosis of, 249–250
 economic burdens of, 251
 ECT for, 257–258
 GDS for, 253–254
 hormone replacement therapy for, 258
 IPT for, 254
 management strategies for, 253–258
 mortality and, 251
 osteoporosis and, 240
 physical burdens of, 250–251
 precipitating factors for, 252
 predisposing factors for, 251–252
 primary prevention approaches to, 260–261
 prognosis for, 259–260
 protective factors against, 252–253
 psychological interventions for, 255–257
 psychotherapeutic interventions for, 255–257
 resistant depression and, 257–258
 risk factors for, 251–253
 secondary prevention approaches to, 260–261
 SSRIs for, 255
 treatment principles for, 254
 learning disabilities, mothers with, 38
 lesbians, addiction among, 185
 Lewy body dementia, 337–338
 licking and grooming arched-back nursing (LG-ABN), 33
 lithium
 for BD, 276–277, 281
 breastfeeding and, 130, 281
 Ebstein's anomaly, 276
 pharmacokinetics of, 130
 during pregnancy, 95–96, 130
 reproductive safety of, 130
 for schizophrenia, 312–313
 lithium baby register, 130
 lofepramine, 255–256
 longevity, for female caregivers, 29
 lorazepam, 258–259
 major depressive disorder (MDD), 271.
 See also depression
 males. *See also* prisoners, male
 ASD diagnoses for, 55–56
 BDD among, 200
 CDT levels in, 176
 cognitive bias in, 56
 criminal offenses by, 148–150
 extreme male brain theory, 57
 gender roles for, evolutionary development of, 56
 gendered power relations and, 1–2
 hormone-induced brain development in, 48
 HPA axis expression in, 234–236
 masculinity for, 5–6, 69
 neuroendocrine system in, 234–236
 panic disorder in, 222–223
 SAD and, 225
 schizophrenia in, 295
 socialization of, 1–6
 steroid hormone regulation in, 48
 systemizing brain in, 56
 Mann, Marty, 189
 masculine culture, 22–23
 masculinity, 5–6, 69
 massage therapy, 113
 maternal caregiving
 in animals, 32–33
 anxiety and, 36–37
 child-centered interventions, 39–40
 depression and, 36–37
 deviation from, 36
 infant attachment and, 32, 38–39
 infants with congenital malformations and, 37–38
 maternal sensitivity compared to, 31–32
 for mothers with learning disabilities, 38
 oxytocin and, 32–34
 parent-centered interventions, 38–39
 maternal caregiving behaviors (MCBs), 31–32
 in animals, 32–33
 maternal depression, childhood exposure to, 109
 maternal sensitivity
 infant attachment formation and, 32
 maternal caregiving compared to, 31–32
 maternal stress
 cortisol and, 82–83
 prenatal development influenced by, 82–83
 MCBs. *See* maternal caregiving behaviors
 MCI. *See* mild cognitive impairment
 MDD. *See* major depressive disorder
 MDQ. *See* Mood Disorder Questionnaire

- memory impairment
 - ERT for, 84–85
 - female hormonal development and, 84–85
 - sex hormones and, 84–85
 - WHIMS, 85
- Meniere’s disease, 253
- menopause. *See* perimenopause
- menstrual cycle
 - anxiety symptoms and, 226–227
 - depression and, 237–238
 - inflammatory responses during, 238
 - PMDD, 83–84, 226
 - PMS, 237–238
- mental health. *See also* Black and ethnic minority women, mental health for domestic violence and, 163–164 double jeopardy risks, 14 environmental influences on, 51 epigenetic influences on, 51 gender-based violence and, 2–3 genetic influences on, 51 poverty as mental health risk, 3 prenatal stress as factor in, 82–83 provisions and practices for, gender-informed, 7–8 sex differences in brain development, 51 survival strategies as part of, 6–7 violent victimisation and, 3
- Mental Health Act, 152
- mental illness. *See also* preconception; pregnancy
 - disclosure of patient information for, 98
 - family planning for, 94
 - female reproduction in, care for, 91–92, 94–98
 - fertility evaluation for, 93–94
 - interagency workings for, 96–97
 - monitoring strategies for, 96
 - multiagency workings for, 97–98
 - non-pharmacological treatments, 93, 96
 - overview of, 90
 - parenting competence for, 94
 - perinatal care plans for, 97
 - pharmacological treatments, 93–94
 - policy implications, 91–92
 - postnatal prevention strategies for, 96
 - prebirth assessments of, by social care, 97
 - reproductive and sexual health and, 91–92, 94–98
 - service care implications, 91–92
 - social care for, 97–98
 - STIs and, 91
 - unplanned pregnancies and, 90
 - untreated, during pregnancy, 95
 - vulnerability in, 90
- mephedrone, 175
- metabolism
 - addiction in women and, 183–184
 - treatment strategies for schizophrenia and, 308–309
- Methods to Improve Diagnostic Assessment and Services (MIDAS) study, 141
- middle age, addiction in, 182
- migration, BME women and, mental health influenced by, 21
- mild cognitive impairment (MCI), 341
- minor depression, 249–250. *See also* unspecified depressive disorder
- mirtazapine, 255–256
- misogyny. *See also* gender inequality embodied distress and, 4
- moclobemide, 255–256
- mood, female hormonal development and, 85
- Mood Disorder Questionnaire (MDQ), 110
- mood disorders. *See also* anti-epileptic mood stabilisers; depression
 - early childhood abuse and, 83
 - prevention strategies, 110–111
 - pubertal development and, 71–72
- mood stabilisers, 312–313. *See also* anti-epileptic mood stabilisers
- moral model, for addiction treatment, 187
- mother-baby units, 113
- murder. *See* homicide
- mutual aid organisations, 189
- Narcotics Anonymous, 189
- needle phobia. *See* blood-injection injury phobia
- negative emotionality, 69
- neonaticide, 151
- postpartum psychosis and, 274
- neuroendocrine system
 - mental illness and, during pregnancy, 107–108
 - sex differences in, 234–236
- neuroepigenetics, 52
- neuroimaging
 - of late onset schizophrenia, 326–327
 - sex differences in, 236–237
 - of VLOS, 326–327
- neuroticism
 - dementia and, 341
 - gender roles and, 69
- neurotransmitters, 107–108
 - serotonergic, sex differences in, 233–234
- non-pharmacological treatments, 93, 96
- nortriptyline, 255–256
- obsessive-compulsive disorder (OCD), 225–226
 - clinical course of, 226
 - comorbidity for, 226
 - depression and, 226
 - differential diagnosis of, 106
 - eating disorders and, 226
 - epidemiology of, 225
 - genetic factors for, 226
 - during pregnancy, 105
 - across reproductive cycle, 226
 - symptoms of, 225–226
- olanzapine, 282, 308
- oligomenorrhoea, 300
- opiate substitution treatment, 188–189
- opponent process theory of addiction, 181
- osteoporosis, 240
 - antidepressant use and, 240
- OT. *See* oxytocin
- oxazepam, 258–259
- oxytocin (OT)
 - ASD and, 60
 - breastfeeding as proxy for, 35–36
 - cross-generational transmission of behavior, 36
 - effects of, 32
 - hormonal synthesis of, 32
 - maternal behavior in animals, 32–33
 - maternal caregiving and, in humans, 32–34
 - pair bonding and, 32
 - perceived parenting experience and, 34–35
 - social affiliation and, 31–35
 - social relationship stress and, 35
- PAFs. *See* population attributable fractions
- paid work, mental resilience through, 3–4
- pair bonding, 32
- panic disorder, 104–105, 222–223
 - BD and, 272
 - clinical course of, 223
 - gender differences and, 222–223
 - prevalence rates for, 222
 - risk factors for, 222–223
 - symptoms of, 222
 - treatment strategies for, 223
- Parental Bonding Instrument (PBI), 34
- Parental Investment Theory, 74–75
- parent-centered interventions, 38–39
- parenting experiences. *See also* adoptive parents; maternal caregiving

Index

- parenting experiences. (cont.)
 child-centered interventions, 39–40
 dementia and, 340
 infant attachment, 32, 38–39
 OT and, 34–35
 PBI, 34
 schizophrenia and, 300–302
 socialization of gender roles and, 66–72
 support interventions, 38–40
 for women with mental illness, 94
 Parkinson's Disease (PD), 327, 338
 paroxetine, 124, 255–256
 paroxysmal tachyarrhythmias, 253
 PATH. *See* Psychological Advocacy Towards Healing
 patient information, disclosure of, 98
 patients and physicians, relationships with, 15
 PBI. *See* Parental Bonding Instrument
 PD. *See* Parkinson's Disease
 perceived parenting experience, 34–35
 perimenopause, depression during, 85, 238–239
 perinatal care planning, 97
 perinatal depression, among BME women, 18
 perinatal psychiatric disorders. *See* pregnancy, mental illness and
 peritraumatic dissociation, 211
 persistent depressive disorder, 102
 persistent hypertension of the newborn (PPHN), 125
 personality. *See also* borderline personality disorder
 adaptive traits, aging and, 249
 affective disorders and, 69–70
 in elderly women, 252
 gender roles and, 69–70
 personality disorders. *See also* borderline personality disorder
 addiction and, 186
 early childhood abuse and, 83
 Emotionally Unstable, 153
 sex differences in, 138
 pharmacokinetics, during pregnancy, 123
 of antidepressants, 124
 of anti-epileptic mood stabilisers, 128
 of antipsychotic drugs, 125–128
 of lithium, 130
 of psychotropic medications, 123
 pharmacological treatments. *See also* antidepressants; anti-epileptic mood stabilisers, during pregnancy; antipsychotic drugs; anxiolytic and hypnotic drugs; lithium; psychotropic medications
 for mental illness, 93–94
 during pregnancy, mental illness and, 112
 for PTSD, 214–215
 summary of, 131–132
 phenothiazines, 126, 258–259
 phobias
 blood-injection injury, 105
 during pregnancy, 105
 social, 105
 physical abuse. *See also* emotional abuse; psychological abuse; sexual abuse
 addiction and, 186
 gender inequality as result of, 1–3
 of girls, 1–2
 hormonal development and, 83
 HPA axis, 83
 mental health implications, 3
 mood disorders and, 83
 personality disorders and, 83
 of women, 1–2
 physicians, patient relationships with, 15
 PMDD. *See* Premenstrual Dysphoric Disorder
 PMS. *See* Premenstrual Syndrome
 population attributable fractions (PAFs), 170
 postpartum blues, 102
 postpartum depression
 clinical presentation of, 102–103
 estrogen treatment for, 111
 prevalence of, 102–104
 prevention strategies for, 110–111
 self-harm and, 103
 suicide and, 103
 postpartum psychosis, 103–104
 BD I and, 270
 infanticide and, 274
 neonaticide and, 274
 oestrogen treatment for, 111
 treatment strategies for, 280–281
 post-traumatic stress disorder (PTSD)
 addiction and, 186
 during adolescence, 209–210
 agoraphobia and, 224
 assessment criteria for, 210–211
 biological factors and, 213–214
 among BME women, 19
 CBT for, 214
 cognitive factors and, 212–213
 cultural factors for, 209
 developmental context for, 209–210
 diagnostic criteria for, 208
 domestic violence and, 162–164
 emotional processing theory and, 213
 environmental factors for, 209
 gender differences in, 209–214
 gender-based violence and, 2–3, 211
 historical development of, 208
 hormonal influences on, 213
 across lifespan, 210
 material support and, 212
 peritraumatic dissociation and, 211
 pharmacotherapy for, 214–215
 phenomenology of, 210–211
 during pregnancy, 105–106
 prevalence rates for, 208–209
 psychological interventions for, 214
 self-blame and, 213
 SNRIs for, 214
 social support and, 212
 SSRIs for, 214
 symptoms of, 164, 208
 trauma type as influence on, 211–212
 treatment strategies for, 214–215
 poverty
 at-risk populations, 3
 gender and, 3
 mental health implications from, 3
 stigma of, 3
 women and, 3
 Power and Control Wheel, 167
 power relations
 gender and, 1–2
 violence and, 1–2
 PPHN. *See* persistent hypertension of the newborn
 preconception. *See also* fetal development
 advice and management for, 93
 assessment of, 92–93
 counseling and, for BD, 273
 counseling and care, for mental illness, 92–94
 defined, 92
 preconception counseling, with BD, 273
 pregabalin, 131, 258–259
 pregnancy, addiction and, 181–182
 alcohol abuse and, 180
 cocaine use and, 181–182
 FASD, 181
 tobacco use and, 182
 pregnancy, mental illness and, 91–92, 94–98. *See also* antidepressants; anti-epileptic mood stabilisers; antipsychotic drugs; anxiolytic and hypnotic drugs; fetal development; lithium; pharmacokinetics; psychotropic medications
 addiction and, 181–182
 adoptive parents and, 114
 anxiety disorders, 104–105, 108–109

- BD, 95, 101–104, 274–280
 biological mechanisms in, 107–108
 biological treatments for, 112–113
 case identification for, 109–110
 CBT for, 111–112
 clinical risk factors for, 106–107
 depression, 101–104, 108–109, 238
 disclosure of patient information, 98
 discontinuation of psychotropic medications, 95–96
 dosage recommendations, 96
 early appointments during, 95
 ECT for, 112–113
 epidemiological risk factors for, 106–107
 fathers and, 114
 first generation antipsychotic drugs for, 282
 GAD, 104
 genetic heritability, 107
 hormonal influences, 107–108
 hormonal therapy for, 112
 if untreated, 95, 108–109
 IPT for, 111–112
 medication strategies for, 95
 mental health monitoring, 96
 neuroendocrine system and, 107–108
 non-pharmacological treatments, 93, 96
 OCD, 105
 panic disorder, 104–105
 perinatal care plans, 97
 pharmacological treatments, 112
 phobias, 105
 postnatal prevention strategies, 96
 postpartum blues, 102
 postpartum depression, 102–104
 postpartum psychosis, 103–104
 pre-birth assessments, by social care, 97
 prevention strategies, 110–111
 psychiatric disorders, clinical presentation of, 101
 psychosocial interventions for, 274–275
 psychosocial risk factors for, 107
 PTSD, 105–106
 for same-sex couples, 114
 schizophrenia, 95
 second generation antipsychotic drugs for, 282–291
 sleep regulation and, 108
 social services for, 98
 special populations affected by, 113–114
 stress-related disorders, 105–106
 supportive therapies for, 111
 trauma-related disorders, 105–106
 treatment settings and, 113
 treatment strategies, 111–114
 unplanned, 90
 pregnancy registers, 122–123
 Premenstrual Dysphoric Disorder (PMDD), 226
 depression and, 83–84, 237
 Premenstrual Syndrome (PMS), 237–238
 BD and, 272–273
 prisoners, male
 mental illness history for, 149–150
 self-harm by, 150
 substance abuse history for, 150
 vulnerable backgrounds for, 149
 prisoners, women
 community interventions for, 155
 conceptual frameworks for, 152–153
 DBT for, 154
 demographics for, 148–155
 dependent children of, 150
 GRT for, 155
 intervention strategies for, 153–155
 male prisoners compared to, 148–150
 mental illness history for, 149–150
 population rates for, 148
 in secure hospitals, 154
 self-harm by, 150
 substance abuse history for, 150–151
 systems of care for, 152
 treatment strategies for, 153–154
 vulnerable backgrounds for, 149
 propranolol, 258–259
 psychodynamic psychotherapy, 313–314
 psychological abuse, 163
 Psychological Advocacy Towards Healing (PATH), 170
 psychosis. *See* postpartum psychosis
 psychotropic medications, during pregnancy, 93. *See also* antidepressants; anti-epileptic mood stabilizers; fetal development; lithium; *specific medications*
 for BD, 276
 breastfeeding and, 123
 discontinuation of, 95–96
 overview of, 122–123
 pharmacokinetics, 123
 pregnancy registers, 122–123
 PTSD. *See* post-traumatic stress disorder
 pubertal development
 affective disorder and, 70–71
 affective disorders and, 73–75
 brain development and, 71–72
 depression and, 237
 emotional processes and, 71–72
 estrogen and, 70–71
 interpersonal stressors and, 72–73
 mood disorders and, 71–72
 testosterone and, 70–71
 pulmonary embolism, 253
 quetiapine, 282
 race, as construct, 14–15
 racism, 22
 raloxifene, 313
 rape, 19
 rapid cycling, with BD, 269
 recall artefact, 65–75
 rejection stress, 235
 relapse, after addiction, 183–184
 reproduction. *See* female reproduction
 reproductive depression, 83–84, 233–239
 resilience
 epigenetics and, 49–51
 through paid work, 3–4
 sex differences and, 50–51
 in women, 50–51
 X chromosome for, 50
 resistant depression, 257–258
 retention, in treatment strategies, 188
 Rett syndrome, 50
 Richards, Laura, 167
 risperidone, 282, 308
 SAD. *See* social anxiety disorder
 same-sex couples
 addiction among, 185
 mental illness and, 114
 schizophrenia. *See also* late onset schizophrenia; treatment strategies, for schizophrenia; very-late-onset-schizophrenia-like-psychosis
 age of onset for, 295–296
 childbirth as influence on, 93
 childhood-onset, 298–299
 clinical presentation of, 296–297
 course of illness for, 296–297
 disease incidence for, 295–296
 early-onset, 298–299
 epidemiology of, 294–295
 estrogen as factor in, 84
 estrogen therapy for, 300, 313
 female reproduction and, 84–86
 hormonal influences on, 300
 hyperprolactinaemia and, 311
 in mothers, 300–302
 during pregnancy, 95
 prevalence rates for, 295–296
 risks to children, 301
 sex differences for, 295, 307
 sex hormones and, 84
 structural brain abnormalities with, 297–300
 symptoms of, 294

Index

- SDN-POA. *See* sexual dimorphic nucleus of the preoptic area
- second generation antipsychotic drugs, 282–291
- secure hospitals, female prisoners in, 154
- selective noradrenaline reuptake inhibitors (SNRIs), 214
- selective serotonin reuptake inhibitors (SSRIs)
- for depression, 124–125, 239–240
 - for late-life depression, 255
 - for PTSD, 214
 - for schizophrenia, 308
- self-blame, 213
- self-harm
- postpartum depression and, 103
 - in prisons, 150
- Sequenced Treatment Algorithm for Depression (STAR-D), 109
- serotonergic neurotransmitters. *See also* oestrogen
- serotonin, 234
 - sex differences for, 233–234
 - sex steroids, 234
 - tryptophan, 234
- serotonin, 234
- sertraline, 124, 255–256
- services development, 7
- for women with mental illness, 91–92
- Severity of Alcohol Dependence Questionnaire, 176
- sex bias, in DSM-IV criteria, 139
- sex differences, in brain development
- brain pathology and, 45
 - epigenetic programming in, 49
 - extreme male brain theory, 57
 - in females, hormone-induced, 48
 - genetic contributions to, 46–47
 - in males, hormone-induced, 48
 - mental health risks and, 51
 - resilience and, 50–51
- sex hormones
- addiction in women and, 184
 - dementia and, 340
 - depression and, 83–84
 - development of, in utero, 81–82
 - estrogen, 70–71, 84
 - memory impairment and, 84–85
 - during perimenopause, 85
 - schizophrenia and, 84
- sex steroids, 234
- sex trafficking, BME women and, 20
- sex workers, addiction behaviours among, 186
- sexual abuse. *See also* child sexual abuse
- addiction and, 162–163
 - criteria for, 162–163
 - HPA axis and, dysregulation of, 235
- sexual dimorphic nucleus of the preoptic area (SDN-POA), 45–46
- sexual health, mental illness and, 91–92.
- See also* female reproduction
 - with schizophrenia, 315
- STIs, 91
- sexual selection
- depression and, 74–75
 - Parental Investment Theory and, 74, 74–75
- sexually transmitted infections (STIs), 91
- shaming, 162–163
- silencing the self, 6
- Silk Road, 175
- sleep regulation, during pregnancy, 108
- SNRIs. *See* selective noradrenaline reuptake inhibitors
- social anxiety disorder (SAD), 224–225
- clinical course for, 225
 - comorbidity for, 225
 - gender differences in, 225
- social camouflage, 57–58
- social constructivism, BPD and, 139–140
- social isolation, 162–163
- social mimicry, 57–58
- social phobia, 105. *See also* social anxiety disorder
- social relationship stress, 35
- social risk hypothesis, 73–75
- social services
- during postnatal period, 98
 - for women with mental illness, 97–98
- socialization, gender and. *See also* gender roles, evolutionary
- development of
 - emotional expression influenced by, 5–6
 - gender intensification hypothesis, 66
 - identity as result of, 1–6
 - masculinity, 5–6
 - parenting and, 66–72
 - self-directed actions and, 6
 - silencing the self, 5–6
- South Asians, depression among, 18
- Spielberg State-Trait Anxiety Inventory (STAI), 110
- spiritual model, for addiction
- treatment, 187
- SSRIs. *See* selective serotonin reuptake inhibitors
- Stages of Change Model. *See* transtheoretical model of behaviour change theory
- STAI. *See* Spielberg State-Trait Anxiety Inventory
- STAR-D. *See* Sequenced Treatment Algorithm for Depression
- Stark, Evan, 162–163
- stereotypes
- cultural, 17
 - in UK, ethnicity as influence on, 22
- steroid hormone regulation, 47–48
- in males, 48
 - for sex steroids, 234
- stigma, of poverty, 3
- STIs. *See* sexually transmitted infections
- stress
- defining parameters for, 234–235
 - dementia and, 341
 - depression and, 73
 - prenatal development influenced by, 82–83
 - pubertal development and, 72–73
 - rejection, 235
 - through social relationships, 35
 - TSST, 35, 235
- stress hormones
- cortisol, 82–83
 - development of, in utero, 82–83
- structured psychotherapies, 111–112
- substance abuse. *See also* addiction;
- alcohol abuse; cocaine use;
 - tobacco use
- BD and, 272–291
 - prisoners and, 150–151
 - schizophrenia treatment and, 314
- subsyndromal depression, 249–250
- sub-threshold depression, 250
- suicide
- addiction and, 185–186
 - aging and, 250
 - postpartum depression and, 103
 - risk factors for, 252
- supportive therapies, 111
- survival strategies, gender influences on, 6–7
- systemizing brain, 56
- tardive dyskinesia (TD), 328
- TCAs. *See* tricyclic antidepressants
- TD. *See* tardive dyskinesia
- telescoping effect, 183
- testosterone
- ASD and, 59–60
 - depression and, 70–71
 - during fetal development, 81–82
 - pubertal development and, 70–71
- thyroid disorder, 253
- tobacco use. *See also* addiction
- during pregnancy, 182
- topiramate, 282
- transtheoretical model of behavior change theory, 181

- trauma. *See also* emotional abuse; physical abuse; post-traumatic stress disorder; psychological abuse; sexual abuse
 hormonal development influenced by, 83
 HPA axis hyperactivity and, 83
 mood disorders as result of, 83
 personality disorders as result of, 83
 type of, 211–212
 trazodone, 255–256
 treatment strategies, for addiction, 187–189
 with addicted partners, 188
 assortive mating and, 188
 barriers to, 188
 models for, 187
 multi-agency approach in, 187
 through mutual aid organisations, 189
 with opiate substitution, 188–189
 outcome data on, 188
 retention in, 188
 through 12 Step programs, 189
 in UK, 181–187
 in US, 181–187
 treatment strategies, for schizophrenia
 with antidepressants, 308, 312
 with antipsychotic medications, 308–309, 311, 310
 BDPs in, 312
 biological differences in, 307–309
 blood volume as factor in, 307–308
 cardiovascular risk from, 311–312
 caregiving approaches to, 314–315
 with CBT, 313–314
 common adverse reactions, 309–316
 gastric emptying and, 307
 gender differences in, 307
 hypnotics in, 312
 with lithium, 312–313
 metabolic factors in, 308–309
 metabolic syndrome from, 311–312
 with mood stabilizers, 312–313
 psychological, 313–314
 receptor binding in, 309–316
 renal clearance and, 309
 resistance to, 313
 service delivery of, 315
 sexual health and, 315
 social considerations in, 314–315
 with SSRIs, 308
 with substance abuse, 314
 with valproate, 312
 tricyclic antidepressants (TCAs), 124
 Trier Social Stress Test (TSST), 35, 235
 Triple P, 39
 tryptophan, 234
 TSST. *See* Trier Social Stress Test
 12 Step programs, 189
 United Kingdom (UK)
 Children's Act in, 98
 cultural assimilation in, 16
 doctor and patient relationships in, cultural influences on, 15
 domestic violence in, 163
 ethnic stereotypes in, 22
 Health and Social Care Act in, 152
 Mental Health Act in, 152
 treatment strategies in, for addiction, 181–187
 United States (US)
 cultural assimilation in, 16
 treatment strategies in, for addiction, 181–187
 unpaid work, 4
 unplanned pregnancies, 90
 unspecified depressive disorder, 102
 untreated maternal BD, 273–274
 in utero, hormonal development
 in females, 81–83
 maternal stress and, 82–83
 for sex hormones, 81–82
 for stress hormones, 82–83
 of testosterone, 81–82
 valproate, 93, 95–96, 128–130
 amenorrhoea and, 311
 anticonvulsant face, 277–291
 for BD, during pregnancy, 278–281
 breastfeeding and, 129–130, 281–282
 fetal valproate syndrome, 277–291
 for schizophrenia, 312
 vascular dementia, 337
 vasopressin, ASD and, 60
 venlafaxine, 240, 255–256
 very-late-onset-schizophrenia-like-psychosis (VLOS)
 AD and, 324–327
 BDPs for, 329
 clinical presentation of, 325–326
 differential diagnosis for, 327–328
 epidemiology of, 321–322
 estrogen hypothesis for, 324
 gender influences on, 323–325
 health impairment with, 323
 historical development of, 320–321
 incidence data on, 321–322
 neurodegenerative processes with, 326–327
 personality as factor for, 323
 prognosis outcomes for, 329–330
 psychotic symptoms, 322
 risk factors for, 322–323
 treatment strategies for, 328–329
 victimisation, mental health and, 3
 violence, gender-based. *See also* domestic violence
 against BME women, 19–20
 criteria for, 162–163
 CSA and, 19
 female prisoners and, 150–151
 FGM, 20
 gender inequality and, 1–3
 gendered power relations and, 1–2
 IPV, 97
 mental health and, implications for, 2–3
 prevalence rates for, 19–20
 PTSD and, 2–3, 211
 rape, 19
 scale of problem, 2
 VLOS. *See* very-late-onset-schizophrenia-like-psychosis
 Waddington, Conrad, 49
 Wernicke-Korsakoff syndrome, 327
 WHIMS. *See* Women's Health Initiative Memory Study
 white matter, in brain development, 72
 WHO. *See* World Health Organisation
 WISE. *See* Women's Ischemia Syndrome Evaluation
 women. *See also* addiction; Black and ethnic minority women; caregivers, women as; criminal offenses, by women; girls; late-life depression
 abuse of, 1–2
 ascertainment bias against, for ASD, 58, 60–61
 in ASD studies, gender bias against, 55
 BDD in, 200
 CDT levels in, 176
 cognitive bias in, 56
 double jeopardy for, 14
 emotional expression for, 5–6
 empathizing brain in, 56
 gender roles for, evolutionary development of, 56
 gender-based violence against, 1–3
 gendered power relations and, 1–2
 hormonal development in utero, 81–83
 hormone-induced brain development for, 48–49
 HPA axis expression in, 234–236
 identification of distress by, 23
 neuroendocrine system in, 234–236
 panic disorder in, 222–223
 poverty and, 3
 recall artefact for, 65–75
 SAD and, 225
 schizophrenia in, 295
 self-directed actions by, 6
 service development for, 7

Index

women. (cont.) silencing the self by, 6 social relationship stress for, 35 socialization of, 1–6	World Health Organisation (WHO) depression predictions, 233 domestic violence action guidelines, 165–166	yoga, 113, 275 young adulthood, addiction development during, 177–179
Women’s Health Initiative Memory Study (WHIMS), 85	X-chromosome, 50	zaleplon, 130–131
Women’s Ischemia Syndrome Evaluation (WISE), 239–240	ASD and, 58	zolpidem, 130–131
		zopiclone, 130–131